Gastric Cancer Pipeline and Clinical Trials Assessment (2023) | Companies – Eli Lilly and Company, Janssen Pharmaceutical, Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol Myers Squibb

Gastric Cancer Pipeline and Clinical Trials Assessment (2023) | Companies - Eli Lilly and Company, Janssen Pharmaceutical, Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol Myers Squibb

DelveInsight’s report titled “Gastric Cancer Pipeline Insight 2023” offers extensive information on more than 230+ companies and over 230+ pipeline drugs in the field of Gastric Cancer research. The report encompasses detailed profiles of the Gastric Cancer pipeline drugs, including information on Gastric Cancer clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.

 

For the Gastric Cancer emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, and route of administration, molecule type, and mechanism of action (MOA). The research on the Gastric Cancer pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, clinical trial studies conducted for Gastric Cancer, any NDA approvals obtained for Gastric Cancer, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

 

To explore more information on the latest breakthroughs in the Gastric Cancer Pipeline treatment landscape of the report, click here @ Gastric Cancer Pipeline Outlook

 

Key Takeaways from the Gastric Cancer Pipeline Report

  • DelveInsight’s Gastric Cancer pipeline report depicts a robust space with 230+ active players working to develop 230+ pipeline therapies for gastric cancer treatment.
  • The leading Gastric Cancer Companies includes EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech,  CARsgen Therapeutics Co., Ltd., Zymeworks Inc.,  NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc.,  Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, and others.
  • Promising Gastric Cancer Pipeline Therapies include Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022,  TCRx_T Cells,  IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410,  PT 886, PRS-343, Oraxol, CA-4948,  Q702,  ACE1702, SI-B001, TT-4, LUM015,  LB 1908, CUE-102,  TORL-2-307-MAB,  OBI-833/OBI-821,  ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110,  LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453,  CCT303-406, VMD-928,  ITI 4000, PAb 001, and others.
  • In December 2022, Daiichi Sankyo and AstraZeneca’s ENHERTU (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
  • In December 2022, RemeGen Co., Ltd. announced on December 7, 2022, that its latest antibody-drug conjugate (ADC), RC118 for injection, has been granted two orphan drug designations (ODD) by the United States Food and Drug Administration (FDA) for gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer. This marks the Company’s fourth, having previously been twice granted ODD for Disitamab Vedotin (RC48) and Telitacicept (RC18) earlier this year.
  • In September 2022, Nuvectis Pharma, Inc. announced positive data for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma.Mice in each group were treated with either vehicle or NXP800, and tumor volumes were measured over 28 days. Treatment with NX800 resulted in tumor regression and substantial tumor growth inhibition versus the control.

 

Gastric Cancer Overview

Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It’s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. Many stomach cancers are linked to lifestyle or environmental factors, including diet.

 

For further information, refer to the detailed Gastric Cancer Unmet Needs, Gastric Cancer Market Drivers, and Gastric Cancer Market Barriers, click here for Gastric Cancer Ongoing Clinical Trial Analysis

 

Gastric Cancer Emerging Drugs Profile

  • IBI308: Innovent Biologics
  • HLX10: Henlix Biotech
  • Pamiparib: BeiGene

 

Gastric Cancer Pipeline Therapeutics Assessment

There are approx. 230+ Gastric Cancer companies which are developing the Gastric Cancer therapies. The Gastric Cancer companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.

 

Request a sample and discover the recent advances in Gastric Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Gastric Cancer Treatment Landscape

 

Gastric Cancer Pipeline Therapeutics Assessment

• Gastric Cancer Assessment by Product Type

• Gastric Cancer by Stage and Product Type

• Gastric Cancer Assessment by Route of Administration

• Gastric Cancer by Stage and Route of Administration

• Gastric Cancer Assessment by Molecule Type

• Gastric Cancer by Stage and Molecule Type

 

Some of the Companies in the Gastric Cancer Therapeutics Market include-

EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech,  CARsgen Therapeutics Co., Ltd., Zymeworks Inc.,  NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc.,  Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, and others

 

Dive deep into rich insights for drugs for Gastric Cancer Pipeline, click here @ Gastric Cancer Unmet Needs and Analyst Views

 

Scope of the Gastric Cancer Pipeline Report

  • Coverage- Global
  • Companies-EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech,  CARsgen Therapeutics Co., Ltd., Zymeworks Inc.,  NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc.,  Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, and others.
  • Gastric Cancer Pipeline Therapies- Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022,  TCRx_T Cells,  IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410,  PT 886, PRS-343, Oraxol, CA-4948,  Q702,  ACE1702, SI-B001, TT-4, LUM015,  LB 1908, CUE-102,  TORL-2-307-MAB,  OBI-833/OBI-821,  ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110,  LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453,  CCT303-406, VMD-928,  ITI 4000, PAb 001, and others.
  • Gastric Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Got Queries? Find out the related information on Gastric Cancer Mergers and acquisitions, Gastric Cancer Licensing Activities @ Gastric Cancer Emerging Drugs, and Recent Trends

 

Table of Content

  1. Introduction
  2. Gastric Cancer Executive Summary
  3. Gastric Cancer: Overview
  4. Gastric Cancer Pipeline Therapeutics
  5. Gastric Cancer Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. IBI308: Innovent Biologics
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Pamiparib: BeiGene
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. HC 5404 FU: HiberCell
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. PolyPEPI 1311: Treos Bio
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Gastric Cancer Companies
  20. Gastric Cancer Products
  21. Gastric Cancer- Unmet Needs
  22. Gastric Cancer- Market Drivers and Barriers
  23. Gastric Cancer- Future Perspectives and Conclusion
  24. Gastric Cancer Analyst Views
  25. Gastric Cancer Key Companies
  26. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services